Intellia Therapeutics, Inc.

NTLA

US45826J1051

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:22:39 08/07/2024 pm IST			5-day change	1st Jan Change
23.34 ^USD	+2.53%		+3.38%	-23.81%

01/07	Intellia Therapeutics, Inc.(NasdaqGM:NTLA) dropped from Russell 3000 Growth Index	CI
01/07	Intellia Therapeutics, Inc.(NasdaqGM:NTLA) dropped from Russell 2000 Growth Index	CI

Intellia Therapeutics, Inc.(NasdaqGM:NTLA) dropped from Russell Small Cap Comp Growth Index

July 01, 2024

Latest news about Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc.(NasdaqGM:NTLA) dropped from Russell 3000 Growth Index	01/07	CI
Intellia Therapeutics, Inc.(NasdaqGM:NTLA) dropped from Russell 2000 Growth Index	01/07	CI
Intellia Therapeutics, Inc.(NasdaqGM:NTLA) dropped from Russell 2500 Growth Index	01/07	CI
Intellia Therapeutics, Inc.(NasdaqGM:NTLA) dropped from Russell Small Cap Comp Growth Index	01/07	CI
Intellia Therapeutics, Inc.(NasdaqGM:NTLA) dropped from Russell 3000E Growth Index	01/07	CI
Intellia Therapeutics Names Edward Dulac CFO	26/06	MT
Intellia Therapeutics, Inc. Announces Executive Changes	26/06	CI
Intellia Therapeutics, Inc. Announces Chief Financial Officer Changes	26/06	CI
Intellia Therapeutics, Inc. Announces Positive Clinical Proof-Of-Concept Data for Redosing A CRISPR-Based Therapy with Its Proprietary LNP-Based Delivery Platform	26/06	CI
Intellia Therapeutics to Present the First-Ever Clinical Data from Patients Redosed with an Investigational in Vivo CRISPR Gene Editing Therapy At the Peripheral Nerve Society Annual Meeting 2024	17/06	CI
Intellia Therapeutics, Inc. Names Brian Goff to its Board of Directors	14/06	CI
Intellia Therapeutics Shares Rise as NTLA-2002 Phase 1 Study Observes 98% Mean Reduction in Monthly Attack Rate	03/06	MT
Transcript : Intellia Therapeutics, Inc. - Special Call	03/06
Intellia Therapeutics' NTLA-2002 Phase 1 Study Observes 98% Mean Reduction in Monthly Attack Rate	03/06	MT
Intellia Therapeutics, Inc. Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002	02/06	CI
Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises	09/05	MT
Transcript : Intellia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024	09/05
Intellia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer	16/04	CI
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	25/03	MT
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	22/03	MT
Intellia Therapeutics Ends Co-Development Agreement With Regeneron	22/03	DJ
Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 3 MAGNITUDE Study of NTLA-2001 as Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy	18/03	CI
Transcript : Intellia Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 03:05 PM	14/03
North American Morning Briefing : Traders Await -2-	26/02	DJ

Chart Intellia Therapeutics, Inc.

Duration

Period

More charts

Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Intellia Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22.76 USD

Average target price

70.72 USD

Spread / Average Target

+210.73%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INTELLIA THERAPEUTICS, INC.	-24.73%	2.2B
MODERNA, INC.	+17.36%	45.34B
LONZA GROUP AG	+42.10%	40.42B
IQVIA HOLDINGS INC.	-10.22%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+32.53%	31.75B
CELLTRION, INC.	-8.98%	27.71B
ICON PUBLIC LIMITED COMPANY	+12.68%	26.52B
UNITED THERAPEUTICS CORPORATION	+43.86%	13.96B
MEDPACE HOLDINGS, INC.	+31.75%	12.44B
BIO-TECHNE CORPORATION	-7.09%	11.26B

Other Biotechnology & Medical Research